MED

Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM Total revenue 140.16 M119 M115.73 M105.56 M89.41 M75.1 M 385.79 M Gross profit 105.67 M88.22 M84.25 M76.64 M62.16 M52.14 M 275.19 M Operating expenses 103.57 M87.47 M85.12 M77.7 M65.63 M59.57 M 288.03 M Selling/general/admin expenses 103.57 M87.51 M85.51 M77.71 M66.24 M59.94 M 289.4 M Research & development —————— — Operating income 2.11 M-15.04 M1.26 M1.07 M4.08 M7.8 M 14.21 M Non-Operating Income, Total 528 K-6.04 M1.79 M3.94 M1.42 M1.42 M 8.57 M Interest expense, net of interest capitalized —————— — Non-Operating Income, excl. Interest Expenses -1.33 M-6.04 M1.3 M1.37 M1.42 M5.88 M 9.97 M Unusual income/expense 1.86 M—487 K2.57 M2 000-4.46 M — Pretax income 1.58 M-20.03 M526 K2.88 M2.66 M-419 K 5.64 M Equity in earnings —————— — Taxes 449 K-4.5 M1.3 M400 K400 K10.93 M 13.03 M Non-controlling/minority interest —————— — After tax other income/expense —————— — Net income before discontinued operations 1.13 M-15.51 M772 K2.48 M2.26 M13.16 M 18.67 M Discontinued operations —————— — Net income 1.13 M-15.51 M772 K2.48 M2.26 M13.16 M 18.67 M Dilution adjustment —————— — Preferred dividends —————— — Diluted net income available to common stockholders 1.13 M-15.51 M772 K2.48 M2.26 M13.16 M 18.67 M Basic earnings per share (Basic EPS) 0.10.08-0.070.23-0.21-1.65 -1.7 Diluted earnings per share (Diluted EPS) 0.10.08-0.070.22-0.21-1.64 -1.7 Average basic shares outstanding 10.94 M10.93 M10.95 M10.99 M10.99 M10.98 M 43.91 M Diluted shares outstanding 10.97 M10.96 M10.95 M11.06 M10.99 M10.98 M 43.98 M EBITDA 5.3 M3.93 M2.4 M2.99 M-24 K-3.97 M 1.4 M EBIT 2.11 M746 K-875 K-1.06 M-3.48 M-7.43 M -12.84 M Cost of revenue 34.49 M30.78 M31.48 M28.91 M27.25 M22.96 M 110.6 M Other cost of goods sold —————— — Depreciation & amortization (cash flow) 3.19 M3.19 M3.28 M4.04 M3.45 M3.46 M 14.24 M